Advertisement

Pharmakologie der Heparine in der Thromboseprophylaxe

  • J. Harenberg
Conference paper

Zusammenfassung

Heparin besteht aus einem Gemisch von Polysacchariden unterschiedlicher Kettenlänge. Die Substanz wurde von McLEAN (1) als gerinnungshemmend erkannt und von HOWELL (2) nach dem Ursprungsort benannt. In kommerziellen Heparinpräparationen mit einem Molekulargewicht von etwa 12.000 Dalton liegen dementsprechend im Mittel 35 Saccharide oder 8–9 Tetrasaccharide vor (3). Die Molekulargewichtsverteilung dieser Präparationen reicht von 3.000 bis 30.000 Dalton. Die gerinnungshemmende Aktivität dieser Heparinfraktionen ist in vitro für Faktor Xa 2,5mal höher als für unfraktionierte Heparine, während die Inhibierung von aPTT etwa gleich ist (4, 5, 6). Die-Faktor-Xa/aPTT-Ratio beträgt, entsprechend für niedermolekulares Heparin, das 2,5fache im Vergleich zu unfraktioniertem Heparin (7).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1).
    McLean J: The thromboplastic action of cephalin. Am J Physiol (1916) 41: 250Google Scholar
  2. 2).
    Howell WH, Holt E: Two new fractions in blood coagulation. Heparin and proantithrom- bin. Amer J Physiol (1918) 47: 328–341Google Scholar
  3. 3).
    Harenberg J, de Vries JX: Characterization of heparins by high performance size exclu- sion liquid chromatography. J Chromatogr (1983) 261: 287–292CrossRefGoogle Scholar
  4. 4).
    Barrowcliffe TW, Johnson A, Eggleton CA, Kemball-Cook G, Thomas DP: Anticoagu- lant activities of high and low-molecular-weight heparin fractions. Brit J Haematol (1979) 41: 573–582CrossRefGoogle Scholar
  5. 5).
    Eggleton CA, Barrowcliffe TW, Merton RE, Thomas DP: In vitro and in vivo studies of the anti Xa activity of heparin. Thromb Res (1981) 24: 319–328PubMedCrossRefGoogle Scholar
  6. 6).
    Lane DA, Mac Gregor IR, Michalski R, Kakkar VV: Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res (1978) 12: 237–246CrossRefGoogle Scholar
  7. 7).
    Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP: An International Standard for Low Molecular Weight Heparin. Thromb Hemostas (1988) 60: 1–7Google Scholar
  8. 8).
    Holmer E: Anticoagulant properties of heparin and heparin fractions. Scand J Haematol (1980b) 24, Suppl 35, 25–34Google Scholar
  9. 9).
    Casu B, Oreste P, Torri G, Zopetti G, Choay J, Lormeau JC, Petitou M: The structure of heparin oligosaccharide fragments with high antifactor Xa activity containing the minimal antithrombin III-binding sequence. Biochem J (1981) 197: 599–609PubMedGoogle Scholar
  10. 10).
    Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G: Structure activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III. Biochem Biophys Res Commun (1983) 116: 492–499PubMedCrossRefGoogle Scholar
  11. 11).
    Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J: Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res (1987) 46: 187–198PubMedCrossRefGoogle Scholar
  12. 12).
    Lam LH, Silbert JE, Rosenberg RD: The separation of active and inactive forms of heparin. Biochem Biophys Res Comm (1976) 69: 570–577PubMedCrossRefGoogle Scholar
  13. 13).
    Estes JW, Pelikan EW, Krüger-Thiemer E: A retrospective study of the pharmcokinetics of heparin Clin. Pharma Therap (1969) 10: 329–337Google Scholar
  14. 14).
    Harenberg J, Stehle G, Augustin J, Zimmermann R: Comparative Human Pharmacology of Low Molecular Weight Heparins. Sem Thromb Hemostas (1989) 15: 414–423CrossRefGoogle Scholar
  15. 15).
    Whitehead MI, MacCarthy TGH: A comparative trial of subcutaneous dodium and calcium heparin as assessed by local haematoma formation and pain. In: Kakkar VV, Thomas DP (eds) Heparin. Chemistry and Clinical Usage. Academic Press, London, New York, San Francisco. (1976) p. 361–366Google Scholar
  16. 16).
    Cade JF, Andrews JT, Stubbs AE: Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med (1982) 12: 501–504PubMedCrossRefGoogle Scholar
  17. 17).
    Thomas DP, Sagar S, Stamatakis JD, Mafei FHA, Erdi A, Kakkar VV: Plasma heparin levels after administration of calcium and sodium salts of heparin. Thromb Res (1976) 9: 241–248PubMedCrossRefGoogle Scholar
  18. 18).
    Johnson EA, Kirwood TBL, Stirling Y, Perezu-Requejo JL, Ingram GIC, Bangham DR, Brozovic M: Four Heparin Preparations: Anti-Xa potentiating effect of Heparin after subcutaneous injection. Thrombos Haemostas (1976) 35: 586–591Google Scholar
  19. 19).
    Harenberg J, Giese Ch, Knödler A, Zimmermann R: Antifactor Xa clotting method for heparin and low molecular weight heparins. Ärztl Lab (1986) 32: 181–184Google Scholar
  20. 20).
    Harenberg J, Giese Ch, Knödler A, Zimmermann R: Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis (1989) 19: 13–20PubMedGoogle Scholar
  21. 21).
    Harenberg J: Pharmacology of Low Molecular Weight Heparins. Sem Thromb Hemostas (1990) 16 Suppl: 12–18Google Scholar
  22. 22).
    Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J: Anticoagulant and lipolytic effects of a low-molecular-weight heparin fraction. Thromb Res (1985) 39: 683–692PubMedCrossRefGoogle Scholar
  23. 23).
    Merton RE, Thomas DP: Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thrombos Haemostas (1987) 58: 839–846Google Scholar
  24. 24).
    Harenberg J, Würzner B, Zimmermann R, Schettler G: Bioavailability and antagonization of the low-molecular-weight heparin CY 216 in man. Thromb Res (1986) 44: 549–555PubMedCrossRefGoogle Scholar
  25. 25).
    Rostin M, Montastruc JL, Houin G, D’Azemar P, Bayrou B, Boneu B: Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations. Fundam Clin Phar ma-col (1990) 4: 17–23CrossRefGoogle Scholar
  26. 26).
    Hobbelen PM, Vogel GM, Meuleman DG: Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res (1987) 48: 549–558PubMedCrossRefGoogle Scholar
  27. 27).
    Hoppensteadt D, Walenga JM, Fareed J.:Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparian sulfate and heparin. Thromb Res (1990) 60: 191–200PubMedCrossRefGoogle Scholar
  28. 28).
    Bang CJ, Berstad A, Talstad I: Gastric mucosal bleeding after unfractionated and low molecular weight heparin in rats. Scand J Gastroenterol (1990) 25: 379–382PubMedCrossRefGoogle Scholar
  29. 29).
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL: Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heprin for 8 days in human volunteers. Thromb Haemost (1989) 61: 357–362PubMedGoogle Scholar
  30. 30).
    Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM: The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol (1988) 28: 609–618PubMedGoogle Scholar
  31. 31).
    Mombelli G, Schaedelin J, Beck EA Pharmakokinetik von Heparin nach einmaliger in-travenöser oder subkutaner Injektion Schweiz Med Wschr (1977) 107: 810–815Google Scholar
  32. 32).
    Esquerre, JP Boneu B, Guiraud R: Kinetics of technetium-labeled heparin in thrombo- embolism: Preliminary report Int J Nucl Med Biol (1979) 6: 215–220PubMedCrossRefGoogle Scholar
  33. 33).
    Teien AN, Bjornson J: Heparin elimination in uraemic patients on haemo-dialysis Scand J Haemat (1976) 17, 19–25Google Scholar
  34. 34).
    Andrassy K, Salzmann W, Saggau W, Storch H, Ritz E: Is more heparin necessary for low-dose heparin prophylaxis in uremic patients? Thrombos Haemostas (1981) 46: 740–742Google Scholar
  35. 35).
    Teien AN: Heparin elimination in patients with liver cirrhosis Thromb Haemostas (1977) 38: 701–705Google Scholar
  36. 36).
    Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL: Heparin Kinetics in Venous Thrombosis and Pulmonary Embolism Circulation, (1976) 53: 691–695Google Scholar
  37. 37).
    Simon TL, Hyers TM, Gaston JP, Harker: LA Heparin pharmacokinetics: increased re- quirements in pulmonary embolism Brit J Haem (1978) 39: 111–120CrossRefGoogle Scholar
  38. 38).
    Mungall D, Raskob G, Coleman R, Rosenbloom D, Ludden T, Hull R: Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol (1989) 29: 896–900PubMedGoogle Scholar
  39. 39).
    Ostergaard PB, Nilsson B, Bergqvist D, Hedner U, Pedersen PC: The effect of low mole-cular weight heparin on experimental thrombosis and haemostasis–the influence of production method. Thromb Res (1987) 45: 739–749PubMedCrossRefGoogle Scholar
  40. 40).
    Psuja P: Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fraction CY 216, CY 222 in patients with uncomplicated myocardial infarction. Folia Haematol Leipz (1988) 115: 661–668Google Scholar
  41. 41).
    Andrew M, Cade J, Buchanan MR, Cerskus AL, Jefferis A, Towell M, Hirsh J: Low mo-lecular weight heparin does not cross the placenta. Thrombos Haemostas (1983) 50: 225Google Scholar
  42. 42).
    Forestier F, Daffos F, Rainaut M, Toulemonde F: Low Molecular Weight Heparin (CY 216) Does Not Cross the Placenta During the Thrid Trimester of Pregnancy. Thromb Haemostas (1987) 57: 234Google Scholar
  43. 43).
    Harenberg J, Leber G, Augustin J, Raedsch R, Schwarz F, Stiehl A, Zimmermann R: Ambulante Langzeitprophylaxe der Thromboembolie mit niedermolekularem Heparin. Klin Wschr (1987) 65: 331–337PubMedCrossRefGoogle Scholar
  44. 44).
    Harenberg J, Schwarz F, Dietz R, Leber G, Zimmermann R, Kübler W: Antikoagulation mit niedermolekularem Heparin bei Patienten mit prothetischem Herzklappenersatz. Z Kardiol (1987) 76: 284–28PubMedGoogle Scholar
  45. 45).
    Harenberg J, Leber G, Zimmermann R, Schmidt W: Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtsh u Frauenheilk (1987) 47: 15–18CrossRefGoogle Scholar
  46. 46).
    Doutremepuich D, Deharo E, Doutremepuich F, Lalanne MC, Toulemonde F: Kinetic study of tPA release induced by heparin and heparin fragment. Thromb Res (1989) 53: 615–621PubMedCrossRefGoogle Scholar
  47. 47).
    Sorensen JV, Bonis LC, Lassen MR, Christiansen HM, Schott P, Olsen AD, Neerstrand HS: Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis–influence of prophylaxis with a low molecular weight heparin. Thromb Res (1990) 59: 131–138PubMedCrossRefGoogle Scholar
  48. 48).
    Eriksson E, Wollter IM, Christenson B, Stigendal L, Risberg B: Heparin and fibrinolysis–comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb Haemost (1988) 59: 284–288PubMedGoogle Scholar
  49. 49).
    Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F: Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. Thromb Haemost (1988) 59: 388–391PubMedGoogle Scholar
  50. 50).
    Agnelli G, Levi M, Cosmi B, ten Cate JW, Nenci GG: Additive effect of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemost (1989) 61: 507–510PubMedGoogle Scholar
  51. 51).
    Rapaport RS, Ronchetti-Blume M, Vogel RL, Hung PP: Heparin potentiates endothelial cell growth factor stimulation of plasminogen activator synthesis by diploid human lung fibroblasts. Thromb Haemost (1988) 59: 514–522Google Scholar
  52. 52).
    Fry ET, Sobel BE: Lack of interference by heparin with thrombolysis or binding of tissue-type plasminogen activator to thrombi. Blood (1988) 71: 1347–1352PubMedGoogle Scholar
  53. 53).
    Millot F, Etienne J, Aiach M, Meyniel D, Brault D, Pieron R, Laruelle P: Effet d’un dérivé de l’héparine de faible poids moléculaire sur la libération d’une activité lipolytique dans la circulation sanguine. C R Acad Sc (1982) 295: 771–776Google Scholar
  54. 54).
    Harenberg J, Stehle G, Dempfle CE, von Hodenberg E, Heene DL: Beeinflussung der Blutgerinnung and der Lipasen durch das niedermolekulare Heparin CY 216. Ärztl Lab (1989) 35: 73–79Google Scholar
  55. 55).
    Broze GJ, Miletich JP: Characterization of the inhibition of tissue factor in serum. Blood (1987 a) 69: 150–155PubMedGoogle Scholar
  56. 56).
    Schmidt M, Barrowcliffe TW, Gray E, Watton J, Harenberg J: Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma. Thromb Res (1991) 63: 503–508PubMedCrossRefGoogle Scholar
  57. 57).
    Lindahl AK, Abildgaard U, Stokke G: Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res (1990) 59: 651–656PubMedCrossRefGoogle Scholar
  58. 58).
    Harenberg J, Schäfer M, Stehle G, Schmidt M, Dempfle CE, Heene DL: Release of the extrinsic inhibitor, hepatic lipase and anti-factor Xa activity into post-heparin plasma. Thromb Haemost (1991) 65: 915Google Scholar
  59. 59).
    Harenberg J, Giese Ch, Knödler A, Zimmermann R, Schettler G: Neutralization of a Low Molecular Weight Heparin Kabi 2165 by Protamine Chloride. Klin Wochenschr (1986) 64: 1171–1175.PubMedCrossRefGoogle Scholar
  60. 60).
    Harenberg J, Gnasso A, de Vries JX, Zimmermann R, Augustin J: Inhibition of lowmolecular-weight heparin by protamine chloride in vivo. Thromb Res (1985) 38: 11–20PubMedCrossRefGoogle Scholar
  61. 61).
    Hubbard AR, Jennings CA: Neutralization of heparan sulphate and low-molecularweight heparin by protamine. Thrombos Haemostas (1985) 13: 86–90Google Scholar
  62. 62).
    Massonnet-Castel S, Pelissier E, Bara L, Terrier E, Abry B, Guibourt P, Swanson J, Jaulmes B, Carpentier A, Samama M: Partial reversal of low-molecular-weight heparin (PK 10169) Anti-Xa activity by protamine sulfate: In vitro and in vivo study during cardiac surgery with extracorporal circulation. Haemostasis (1986) 16: 139–145PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • J. Harenberg
    • 1
  1. 1.1. Medizinische KlinikFakultät für Klinische Medizin Mannheim der Universität HeidelbergMannheimDeutschland

Personalised recommendations